Hu et al. reported that DOX treatment resulted into miR-200a downregulation both in vivo and in vitro, overexpression of miR-200a alleviated DOX-induced cardiac atrophy and cardiac dysfunction via nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation (136). Here, NFE2L2 is linked to Atrophy.